Taysha Gene Therapies, Inc. - Common Stock (TSHA) stock analysis
TSHA · Taysha Gene Therapies, Inc. - Common Stock
Latest recorded price: USD 4.06
Sector and industry: Healthcare · Biotechnology
Fiscal 2025 figures: revenue growth 57.5%, free cash flow margin -960.1%. The model flags 1 risk signal for this company (1 high severity).